Acadia Pharmaceuticals ACAD Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $282.21M+29.6% | $177.7M-44.4% | $258M+66.3% | $253.64M+43.2% | $217.7M+6.3% | ||
| $569.25M+22.7% | $641.99M+47.1% | $589.02M+43.6% | $508.36M+57.0% | $463.88M+74.5% | ||
| $135.35M+28.0% | $121.46M+23.0% | $115.85M+18.0% | $107.51M+3.7% | $105.74M+11.7% | ||
| -$78K-101% | $4.89M+10.6% | $0-100% | $4.1M-84.9% | $10.45M-37.2% | ||
| $1.1B+25.8% | $1.06B+13.2% | $1.08B+36.6% | $960.55M+31.8% | $870.94M+29.0% | ||
| $14.65M+319% | $7.51M+78.2% | $3.71M-7.0% | $3.55M-14.4% | $3.5M-20.0% | ||
| $106.17M-9.3% | $108.89M-9.1% | $111.62M+5.8% | $114.34M+6.0% | $117.06M+6.2% | ||
| $1.61B+41.8% | $1.56B+31.7% | $1.33B+36.2% | $1.23B+34.1% | $1.13B+32.4% | ||
| $305.52M+1.0% | $277.11M-29.8% | $356.58M+3.7% | $330.02M-2.3% | $302.53M-8.5% | ||
| $357.16M-2.7% | $336.81M-26.0% | $413.5M+3.5% | $403.17M+1.5% | $367.13M-6.1% | ||
| $16K0.0% | $16K0.0% | $16K0.0% | $16K0.0% | $16K0.0% | ||
| -$1.81B+17.2% | -$1.81B+17.7% | -$2.09B+11.1% | -$2.16B+9.3% | -$2.19B+9.5% | ||
| $1.25B+63.1% | $1.23B+67.5% | $917.27M+58.9% | $822.38M+59.2% | $765.24M+64.9% | ||
| $1.61B+41.8% | $1.56B+31.7% | $1.33B+36.2% | $1.23B+34.1% | $1.13B+32.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Acadia Pharmaceuticals's total assets?
- Acadia Pharmaceuticals (ACAD) holds $1.6B in total assets, up 41.8% year over year.
- How much debt does Acadia Pharmaceuticals have?
- Acadia Pharmaceuticals carries $50.8M in total debt against $1.2B of shareholders' equity, a debt-to-equity ratio of 0.04.
- How much cash does Acadia Pharmaceuticals have?
- Acadia Pharmaceuticals holds $282.2M in cash and equivalents.
- Can Acadia Pharmaceuticals cover its short-term obligations?
- Its current ratio is 3.59 — current assets exceed current liabilities.
- Where does Acadia Pharmaceuticals's balance sheet data come from?
- Every line is extracted from Acadia Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
